Linked magnolol dimer as a selective PPARγ agonist – Structure-based rational design, synthesis, and bioactivity evaluation

• Published in: Scientific reports Vol. 7; no. 1; pp. 13002 - 10
• Main Authors: Dreier, Dominik, Latkolik, Simone, Rycek, Lukas, Schnürch, Michael, Dymáková, Andrea, Atanasov, Atanas G., Ladurner, Angela, Heiss, Elke H., Stuppner, Hermann, Schuster, Daniela, Mihovilovic, Marko D., Dirsch, Verena M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.10.2017; Nature Publishing Group
• Subjects: 13; 38; 42/109; 631/154/436; 639/638; Biological activity; Crystal structure; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Dimerization; Humanities and Social Sciences; Ligands; Metabolic syndrome; multidisciplinary; Nuclear receptors; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-12628-5

The nuclear receptors peroxisome proliferator-activated receptor γ (PPARγ) and its hetero-dimerization partner retinoid X receptor α (RXRα) are considered as drug targets in the treatment of diseases like the metabolic syndrome and diabetes mellitus type 2. Effort has been made to develop new agonists for PPARγ to obtain ligands with more favorable properties than currently used drugs. Magnolol was previously described as dual agonist of PPARγ and RXRα. Here we show the structure-based rational design of a linked magnolol dimer within the ligand binding domain of PPARγ and its synthesis. Furthermore, we evaluated its binding properties and functionality as a PPARγ agonist in vitro with the purified PPARγ ligand binding domain (LBD) and in a cell-based nuclear receptor transactivation model in HEK293 cells. We determined the synthesized magnolol dimer to bind with much higher affinity to the purified PPARγ ligand binding domain than magnolol ( K i values of 5.03 and 64.42 nM, respectively). Regarding their potency to transactivate a PPARγ-dependent luciferase gene both compounds were equally effective. This is likely due to the PPARγ specificity of the newly designed magnolol dimer and lack of RXRα-driven transactivation activity by this dimeric compound.